NCT02601313 2026-03-18
ZUMA-2
Gilead Sciences
Phase 2 Completed
Clinical Trials
9 trialsNCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT05041309 2026-02-25
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Gilead Sciences
Enrolling by invitation
NCT06253663 2025-12-16
JKART-1
Gilead Sciences
Phase 2 Active not recruiting
NCT04880434 2025-11-17
ZUMA-2
Gilead Sciences
Phase 2 Completed
NCT02625480 2025-09-29
ZUMA-4
Gilead Sciences
Phase 1/2 Active not recruiting
NCT05776134 2025-01-10
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
NCT03624036 2023-11-18
ZUMA-8
Gilead Sciences
Phase 1 Terminated
NCT04162756 2021-10-14
ZUMA-18
Gilead Sciences
Approved for marketing